Viral vaccine manufacturing platforms: Meiji Holdings Last 5 Years research landscape
Virus particles lose structural integrity and immunogenicity during purification and storage, requiring specialized stabilization and inactivation protocols to ensure clinical safety.
What technical problems is Meiji Holdings addressing in Viral vaccine manufacturing platforms?
Multivalent liquid formulation instability
(8) documents
Interaction between diverse bacterial antigens like Hib and HepB causes physical instability in prefilled liquid combinations.
Viral replication yield constraints
(17) documents
Low viral titers in attenuated strains like SARS-CoV-2 or Dengue limit manufacturing productivity and purification efficiency.
Vlp structural deformation
(6) documents
Virus-like particles and fixed virions lose native conformational epitopes if not stabilized by specific covalent cross-linking.
Glycoprotein immunogenicity deficits
(9) documents
Recombinant envelope proteins for CMV and RSV often fail to induce sufficient neutralizing antibody titers without chimeric modification.
